1Cancers du sein. Recommendations pour la pratique clinique de Saint - Paul - de - Vence [ J ]. Oncologie, 2005,7 ( 5 ) : 342 - 379.
2Cohen I, Perel E, Tepper M, et al. Dose - dependent effect of tamoxifen therapy on endometrial pathologies in postmenopausal breast cancer parents[ J ]. Breast Cancer Res Treat, 1999,53 (3) : 255 - 262.
3Dombernowsky P, Smith I, Falkson G, et al. Letrozole, a new oral aromatase inhibitor for advaneed breast eaneer: Double - blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate [ J ]. J Clin Oncol, 1998,16(2) :453 -461.
4Breast International Group. Letrozole vs tamixifen as adjuvant endocrine therapy for postmenopausal women with receptor positive breast cancer: BIG1 - 98, a prospective randomized double - blind phase Ⅲ study[ J]. N Engl J Med,2005,353 (26):2747 - 2758.
5Chung CT, Carlson Rw. The role of aromatase inhibitors in early breast cancer[J]. Curt Treat Options Oncol, 2003,4(2) :133 - 140.
6Buzdar AU. New generation aromatase inhibitors -from the advanced to the adjuvant setting [ J]. Breast Cancer Res Treat, 2002,75 ( 1 ) :13 - 17.
7Kaufmann M, Bajetta E, Dirix LY, et al. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: Results of a phase Ⅲ randomized double - blind trial [J]. Clin Oncol, 2000,18 ( 7 ) : 1399 - 1411.
6Osborne CK. Adjuvant endocrine therapy//Harris, Lippman, Morrow, et al. Diseases of the breast.3rd Ed.USA. Lippincott: Williams&Wilkins, 2004: 865-891.
7Early Breast Cancer Trialists'Collaborative Group. Tamoxifen for early breast cancer: an overview of rasldomized trials. Lancet, 1998, 351 (9114): 1451-1467.
8Eisen A, Tmdeau M, Shelley W, et al. Aromatase inhibitors m adjuvant therapy for hormone receptor positive breast cancer.. A systematic review, Cancer Treat Rev, 2008, 34 (2): 157-174.
9de Cremoux P, Di6ras V, Poupon MF, et al. Tamoxifen and aromatase inhibitors in the treatment of breast cancer in menopausal women: pharmacological and clinical aspects. Bull Cancer, 2004, 91 (12): 917-927.
